Gross M D, Shapiro B, Francis I R, Glazer G M, Bree R L, Arcomano M A, Schteingart D E, McLeod M K, Sanfield J A, Thompson N W
Department of Internal Medicine, University of Michigan, Ann Arbor.
J Nucl Med. 1994 Jul;35(7):1145-52.
We studied 229 patients with abnormal adrenal anatomy depicted by CT who were without biochemical evidence of endocrine dysfunction using the presence of 131I-6 beta-iodomethyl-nor-cholesterol (NP-59) adrenal gland uptake as an index of differential adrenal function in the evaluation of the clinically "silent" adrenal mass lesion.
NP-59 (1 mCi) was injected intravenously with posterior and lateral abdominal images obtained 5-7 days postinjection.
One-hundred and fifty-nine of 185 patients with unilateral adrenal enlargement on CT had scintigraphic evidence that the mass represented a functioning (NP-59 avid) but not hypersecretory, (biochemically normal) adrenal cortical adenoma (concordant imaging pattern). Forty-one of 44 patients with intra-adrenal neoplasms were depicted on scintigraphy as decreased or absent NP-59 accumulation on the side of the adrenal mass (discordant imaging pattern). In this study, sensitivity was 71% (41 of 58 patients; 95% confidence interval (CI), 58% to 88%); specificity was 100% (171 of 171 patients; 95% CI, 95% to 100%) and accuracy was 93% (212 of 229 patients; 95% CI, 88% to 96%).
These data confirm our earlier observations that the functional information depicted by scintigraphy complements the morphological evaluation by CT and in the absence of hormonal dysfunction, the presence of concordant CT and 131I-NP-59 scans are characteristic of functioning, but not hypersecretory, benign adrenocortical adenomas. Conversely, discordant CT and 131I-NP-59 scans are suggestive of nonfunctioning, space-occupying, adrenal lesions.
我们研究了229例CT显示肾上腺解剖结构异常但无内分泌功能障碍生化证据的患者,使用131I-6β-碘甲基去甲胆固醇(NP-59)肾上腺摄取情况作为鉴别肾上腺功能的指标,来评估临床上“无症状”的肾上腺肿块病变。
静脉注射NP-59(1毫居里),并在注射后5 - 7天获取腹部后位和侧位图像。
185例CT显示单侧肾上腺增大的患者中,159例的闪烁扫描证据表明肿块为有功能(NP-59摄取活跃)但无分泌亢进(生化指标正常)的肾上腺皮质腺瘤(影像表现一致)。44例肾上腺内肿瘤患者中,41例在闪烁扫描中显示肾上腺肿块侧NP-59摄取减少或缺失(影像表现不一致)。在本研究中,敏感性为71%(58例患者中的41例;95%置信区间(CI),58%至88%);特异性为100%(171例患者中的171例;95% CI,95%至100%),准确性为93%(229例患者中的212例;95% CI,88%至96%)。
这些数据证实了我们早期的观察结果,即闪烁扫描所显示的功能信息补充了CT的形态学评估,并且在无激素功能障碍的情况下,CT与131I-NP-59扫描结果一致是有功能但无分泌亢进的良性肾上腺皮质腺瘤的特征。相反,CT与131I-NP-59扫描结果不一致提示肾上腺存在无功能的占位性病变。